BioCentury
ARTICLE | Company News

Biomics Biotechnologies, Benitec deal

August 17, 2015 7:00 AM UTC

Benitec purchased Biomics’ share in DNA-directed RNAi (ddRNAi)-based HBV drug candidate Hepbarna, which the companies had been developing under a JV. Benitec now has exclusive, worldwide rights to develop and commercialize the preclinical product. ...